GeneDx Holdings (WGS) Capital Expenditures (2020 - 2026)

GeneDx Holdings (WGS) has reported Capital Expenditures for 7 consecutive years, with $10.1 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Capital Expenditures rose 326.93% year-over-year to $10.1 million in Q2 2026; TTM through Jun 2026 was $27.1 million, a 122.13% increase from a year earlier, with the FY2025 full-year figure at $19.0 million, up 246.33% from the prior year.
• Capital Expenditures was $10.1 million for Q2 2026 at GeneDx Holdings, up from $6.5 million in the prior quarter.
• Over five years, Capital Expenditures peaked at $10.1 million in Q2 2026 and troughed at $112000.0 in Q3 2023.
• A 5-year average of $3.0 million and a median of $2.2 million in 2022 frame the typical range for Capital Expenditures.
• Across the five-year window, Capital Expenditures plunged 94.5% in 2023 and soared 1283.52% in 2025, its largest moves.
• Over 5 years, Capital Expenditures stood at $672000.0 in 2022, then jumped by 253.57% to $2.4 million in 2023, then gained by 21.17% to $2.9 million in 2024, then jumped by 50.99% to $4.3 million in 2025, then soared by 132.67% to $10.1 million in 2026.
• The last three Capital Expenditures figures came in at $10.1 million (Q2 2026), $6.5 million (Q1 2026), and $4.3 million (Q4 2025), per Business Quant data.